RPA2C Antibody

What is RPA2 and what cellular functions does it perform?

RPA2 (also known as RPA32/RPA2) is a 29 kDa subunit of the heterotrimeric Replication Protein A (RPA) complex that binds to single-stranded DNA (ssDNA), forming a nucleoprotein complex. This complex plays critical roles in DNA metabolism, including DNA replication, repair, recombination, and telomere maintenance. RPA2 also coordinates cellular responses to DNA damage through activation of the ataxia telangiectasia and Rad3-related protein (ATR) kinase .

The RPA complex has two different binding modes (low-affinity and high-affinity) for ssDNA, which are determined by which oligonucleotide/oligosaccharide-binding (OB) domains are utilized. RPA2 contains a single OB domain that participates in high-affinity DNA binding and also features a winged helix domain at its carboxy terminus that interacts with many genome maintenance proteins .

What are the key characteristics of commercially available RPA2 antibodies?

Commercial RPA2 antibodies typically share several important characteristics:

• Host Species: Predominantly rabbit-derived

• Clonality: Available in both polyclonal and monoclonal formats

• Reactivity: Primary reactivity against human RPA2

• Applications: Validated for Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), flow cytometry, and ELISA depending on the specific antibody

• Recognition: Target the full-length RPA2 protein or specific epitopes

• Molecular Weight Detection: Approximately 29 kDa

• Storage Conditions: Typically stored at -20°C in buffer solutions containing glycerol or in lyophilized form

How does RPA2 relocalize in response to DNA damage?

• RPA2 relocates to discrete nuclear foci, which represent sites of DNA damage processing

• These nuclear foci often co-localize with other DNA damage response proteins

• RPA2 is also present in PML (promyelocytic leukemia) nuclear bodies, which are implicated in various cellular processes including DNA damage response

This relocalization is often accompanied by hyperphosphorylation of RPA2, which can be detected as a mobility shift in Western blot analysis and serves as a marker for activation of the DNA damage response pathway .

What are the optimal conditions for using RPA2 antibodies in Western blot analysis?

For optimal Western blot results with RPA2 antibodies, follow these methodological guidelines:

• Sample Preparation:

  • Load 50μg protein per lane under reducing conditions

  • Use validated cell lines such as U20S, Jurkat, K562, A549, Raji, HeLa, HUVEC, or HepG2

• Electrophoresis Parameters:

  • Use 5-20% SDS-PAGE gels

  • Run at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours

• Transfer Conditions:

  • Transfer to nitrocellulose membrane at 150mA for 50-90 minutes

• Blocking:

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Antibody Incubation:

  • Primary antibody: 0.5 μg/mL, overnight at 4°C or dilution of 1:500-2000

  • Secondary antibody: Anti-rabbit IgG-HRP at 1:5000 dilution for 1.5 hours at room temperature

• Washing:

  • Wash with TBS-0.1% Tween, 3 times for 5 minutes each

• Detection:

  • Use enhanced chemiluminescence (ECL) detection

  • Expected band size: approximately 29 kDa

How should I optimize immunohistochemistry protocols for RPA2 detection in tissue samples?

For effective RPA2 detection in tissue sections by immunohistochemistry:

• Sample Preparation:

  • Use paraffin-embedded tissue sections

  • Human mammary cancer and breast cancer tissues have been validated for RPA2 antibodies

• Antigen Retrieval:

  • Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • This step is critical for exposing the RPA2 epitope that may be masked during fixation

• Blocking:

  • Block with 10% goat serum to reduce non-specific binding

• Antibody Incubation:

  • Primary antibody: Use at 1μg/ml concentration, incubate overnight at 4°C or at a dilution of 1:30-150

  • Secondary antibody: Biotinylated goat anti-rabbit IgG, incubate for 30 minutes at 37°C

• Detection System:

  • Apply Streptavidin-Biotin-Complex (SABC) with DAB as the chromogen

  • This provides a sensitive detection system for visualizing even low-abundance proteins

• Controls:

  • Include negative controls (omitting primary antibody)

  • Include positive control tissues with known RPA2 expression

What is the best approach for using RPA2 antibodies in immunofluorescence studies?

For optimal immunofluorescence detection of RPA2:

• Cell Preparation:

  • HeLa cells have been validated for RPA2 immunofluorescence staining

  • Fix cells appropriately (4% paraformaldehyde is commonly used)

• Antigen Retrieval:

  • Perform enzyme antigen retrieval for 15 minutes using IHC enzyme antigen retrieval reagent

• Blocking:

  • Block with 10% goat serum

• Antibody Incubation:

  • Primary antibody: Use at 4μg/mL concentration, incubate overnight at 4°C

  • Secondary antibody: DyLight®488 Conjugated Goat Anti-Rabbit IgG at 1:100 dilution, incubate for 30 minutes at 37°C

• Nuclear Counterstaining:

  • Counterstain with DAPI to visualize nuclei

• Visualization:

  • Use a fluorescence microscope with appropriate filter sets for the fluorophores used

  • Look for nuclear localization with possible focal patterns, especially after DNA damage induction

• Analysis:

  • Quantify foci number, size, and intensity

  • For co-localization studies, use appropriate secondary antibodies with distinct fluorophores

What are the common issues encountered in RPA2 Western blotting and how can they be resolved?

When working with RPA2 antibodies in Western blotting, researchers may encounter several challenges:

• Multiple bands or non-specific binding:

  • Increase blocking time or concentration

  • Optimize antibody dilution within the recommended range (1:500-2000)

  • Use more stringent washing conditions (increase Tween-20 concentration or washing duration)

  • Verify antibody specificity - validated antibodies should show minimal cross-reactivity

• Weak or absent signal:

  • Increase protein loading (up to 50μg as used in validation studies)

  • Reduce antibody dilution while staying within recommended range

  • Extend primary antibody incubation time (overnight at 4°C)

  • Verify RPA2 expression in your cell type - use validated cell lines as positive controls

  • Check transfer efficiency, especially for longer transfer times

• Inconsistent results between experiments:

  • Standardize lysate preparation methods

  • Include consistent positive controls in each experiment

  • Maintain consistent incubation times and temperatures

  • Use freshly prepared reagents, especially detection substrates

• Phosphorylation-dependent mobility shifts:

  • RPA2 undergoes phosphorylation after DNA damage, resulting in higher molecular weight bands

  • If studying phosphorylation states, treat samples with phosphatase to confirm phosphorylation-dependent shifts

  • Consider using phospho-specific antibodies for detailed analysis

How can I distinguish between RPA2 signals in normal replication versus DNA damage contexts?

Differentiating RPA2 functions in normal replication versus damage response requires specific experimental approaches:

• Phosphorylation Analysis:

  • Normal replication: RPA2 shows minimal phosphorylation

  • DNA damage: RPA2 becomes hyperphosphorylated, visible as higher molecular weight bands in Western blot

  • Use control and DNA damage-treated samples side by side for comparison

• Localization Patterns:

  • Normal conditions: Diffuse nuclear staining or small foci during S-phase

  • DNA damage: Redistribution to discrete nuclear foci, as noted in the antibody characteristics

  • Quantify focal patterns (number, size, intensity) to distinguish between contexts

• Cell Cycle Correlation:

  • Combine RPA2 staining with cell cycle markers

  • Normal S-phase cells will show some RPA2 staining associated with replication

  • DNA damage-induced RPA2 foci can occur throughout the cell cycle

• Co-localization Analysis:

  • Normal replication: Co-localization with replication markers (PCNA, EdU)

  • DNA damage: Co-localization with damage markers (γH2AX, 53BP1)

  • Perform dual immunofluorescence staining for definitive distinction

• Time-course Analysis:

  • DNA damage-induced RPA2 foci persist longer than replication-associated foci

  • Monitor temporal dynamics to distinguish between transient replication events versus damage response

What controls should be included when using RPA2 antibodies in research applications?

To ensure experimental rigor when working with RPA2 antibodies, include these essential controls:

• Positive Controls:

  • Cell lines with confirmed RPA2 expression such as U20S, Jurkat, K562, A549, Raji, HeLa, HUVEC, and HepG2

  • Treatment controls (e.g., UV irradiation or hydroxyurea) to induce RPA2 phosphorylation or relocalization

• Negative Controls:

  • For immunostaining: Omit primary antibody but include secondary antibody

  • For Western blot: Consider RPA2-depleted samples (siRNA knockdown) if available

  • For flow cytometry: Include isotype control antibody as shown in validation studies

• Specificity Controls:

  • Rabbit IgG control at equivalent concentration to test non-specific binding

  • Pre-incubation with blocking peptide if available

  • Multiple antibodies recognizing different epitopes of RPA2 to confirm specificity

• Technical Controls:

  • Loading controls for Western blot (β-actin, GAPDH, etc.)

  • Nuclear counterstain for immunofluorescence to confirm subcellular localization

  • Background fluorescence controls (unstained cells) for flow cytometry

• Validation Controls:

  • Verify expected molecular weight (approximately 29 kDa)

  • Confirm nuclear localization and redistribution upon DNA damage

  • Compare results across multiple detection methods when possible

How can RPA2 antibodies be utilized to study DNA damage response pathway activation?

RPA2 antibodies serve as powerful tools for investigating DNA damage response (DDR) activation:

• Monitoring DDR Kinase Activities:

  • RPA2 is phosphorylated by multiple DDR kinases (ATR, ATM, DNA-PK)

  • Western blotting can detect mobility shifts indicative of hyperphosphorylation

  • Time-course experiments can reveal the kinetics of pathway activation

• Pathway-specific Responses:

  • Different DNA damaging agents induce distinct phosphorylation patterns

  • Compare UV, ionizing radiation, replication inhibitors, and topoisomerase poisons

  • Correlate RPA2 status with activation of downstream effectors

• Checkpoint Activation Analysis:

  • Combine RPA2 analysis with cell cycle markers

  • Monitor checkpoint-dependent cell cycle arrests

  • Correlate RPA2 phosphorylation status with checkpoint maintenance and recovery

• Single-cell Analysis:

  • Flow cytometry can quantify RPA2 levels across cell populations

  • Identify subpopulations with differential DDR activation

  • Correlate with cell cycle phase and other markers

• Spatial Organization of Repair:

  • Immunofluorescence reveals RPA2 relocalization to nuclear foci

  • Track the assembly and disassembly of repair complexes

  • Analyze co-localization with other DDR factors

What methods can I use to study RPA2 involvement in replication stress responses?

To investigate RPA2's role in replication stress:

• Chromatin Fractionation:

  • Separate soluble and chromatin-bound proteins

  • Assess RPA2 recruitment to chromatin during replication stress

  • Compare normal versus stressed conditions to quantify chromatin association

• Replication Fork Analysis:

  • Combine RPA2 immunostaining with DNA fiber analysis

  • Correlate RPA2 binding with fork stalling, collapse, or restart

  • Use pulse-chase approaches (EdU/BrdU) to mark active replication sites

• Protein-Protein Interaction Studies:

  • Identify stress-induced changes in RPA2 interaction partners

  • Perform co-immunoprecipitation under different stress conditions

  • Analyze post-translational modifications that regulate these interactions

• High-resolution Microscopy:

  • Use super-resolution techniques to analyze RPA2 assembly at stalled forks

  • Quantify nanoscale organization of replication stress sites

  • Track dynamic changes in real-time using live-cell imaging

• Genetic Perturbation Analysis:

  • Manipulate replication stress response factors

  • Assess impact on RPA2 phosphorylation and recruitment

  • Correlate with replication fork stability and cell survival

How can I design experiments to investigate the interplay between RPA2 and other DNA repair factors?

To study interactions between RPA2 and other repair proteins:

• Sequential Recruitment Analysis:

  • Perform time-course experiments after DNA damage induction

  • Use immunofluorescence to track the order of factor recruitment

  • Compare recruitment kinetics across different damage types

• Depletion/Inhibition Studies:

  • Deplete or inhibit specific repair factors

  • Assess impact on RPA2 recruitment, phosphorylation, and dynamics

  • Use complementary approaches (genetic and pharmacological)

• Domain Mapping:

  • Express RPA2 variants with mutations in key functional domains

  • Analyze effects on interactions with repair factors

  • Correlate structural features with functional outcomes

• Damage-specific Analysis:

  • Induce different types of DNA lesions (DSBs, crosslinks, base damage)

  • Compare RPA2 responses and interactions across damage types

  • Identify pathway-specific versus general responses

• Proximity Ligation Assays:

  • Directly visualize protein-protein interactions in situ

  • Quantify interactions under different conditions

  • Assess spatial distribution of interaction complexes

The antibody-cell conjugation (ACC) technology described in recent research represents a promising approach for developing new therapeutic strategies based on targeting RPA2 or its interacting proteins in disease contexts .

What considerations are important when using RPA2 antibodies for cancer research applications?

When applying RPA2 antibodies in cancer research:

• Tumor Type Considerations:

  • Validated in human mammary and breast cancer tissues

  • Expression and localization patterns may vary across cancer types

  • Compare with matched normal tissues when possible

• Sample Processing:

  • Optimize fixation and antigen retrieval for clinical specimens

  • Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) works well for RPA2

  • Consider tissue microarrays for high-throughput analysis

• Correlation with Clinical Parameters:

  • Analyze RPA2 expression/phosphorylation relative to:

    • Patient outcomes

    • Treatment responses

    • Genomic instability markers

• Therapy Response Monitoring:

  • RPA2 phosphorylation serves as a biomarker for DNA damaging therapies

  • Compare pre- and post-treatment samples

  • Correlate with tumor response metrics

• Combination with Other Markers:

  • Integrate RPA2 analysis with other DDR markers

  • Develop multiparameter panels for comprehensive profiling

  • Consider RPA2 status in the context of p53, BRCA1/2, and other relevant factors

Recent advances in antibody-cell conjugation technology offer new possibilities for developing targeted therapies that might leverage RPA2's specificity in cancer cells with high replication stress or defective DNA repair .

What is the significance of different RPA2 phosphorylation patterns observed in Western blot analysis?

RPA2 phosphorylation patterns provide valuable insights into cellular responses:

• Unphosphorylated Form (29 kDa):

  • Predominantly observed in unperturbed cells

  • Represents the baseline state of RPA2

• Moderately Phosphorylated Forms (30-31 kDa):

  • Often associated with normal cell cycle progression

  • Can indicate mild replication stress

  • Typically involves phosphorylation at Ser23 and Ser29

• Hyperphosphorylated Forms (32-34 kDa):

  • Indicative of significant DNA damage or severe replication stress

  • Involves multiple phosphorylation sites (Ser4/8, Thr21, Ser33)

  • Associated with checkpoint activation and replication inhibition

• Interpretation Guidelines:

  • Gradual shifts suggest progressive phosphorylation events

  • Distinct bands indicate specific phosphorylation states

  • Pattern changes over time reflect DDR kinetics

• Kinase-specific Patterns:

  • ATR primarily phosphorylates Thr21 and Ser33

  • DNA-PK and ATM target Ser4/8

  • CDKs phosphorylate Ser23 and Ser29 during normal cell cycle

Western blot validation data from multiple cell lines shows the expected 29 kDa band under normal conditions, providing a baseline for comparison with damage-induced states .

How should I analyze and quantify RPA2 foci in immunofluorescence experiments?

For rigorous analysis of RPA2 foci in immunofluorescence images:

• Image Acquisition Parameters:

  • Maintain consistent exposure settings across samples

  • Capture multiple z-stacks if using confocal microscopy

  • Include DAPI counterstain for nuclear definition

• Quantification Approaches:

  • Manual counting: For limited sample sizes or when qualitative assessment is sufficient

  • Semi-automated: Use ImageJ/Fiji with appropriate thresholding

  • Fully automated: Consider CellProfiler or commercial high-content systems for large datasets

• Key Metrics to Measure:

  • Foci number per nucleus

  • Foci size distribution

  • Foci intensity

  • Nuclear versus cytoplasmic signal

  • Co-localization coefficients with other proteins

• Statistical Analysis:

  • Analyze sufficient cell numbers (typically >100 per condition)

  • Apply appropriate statistical tests (t-test, ANOVA, non-parametric alternatives)

  • Consider cell cycle phase in your analysis

• Visualization Methods:

  • Present representative images alongside quantification

  • Use consistent contrast/brightness settings

  • Include scale bars and magnification information

The immunofluorescence validation images from source show nuclear localization of RPA2 in HELA cells and can serve as reference for normal distribution patterns.

What experimental approach should I use to study RPA2's role in maintaining genome stability?

To investigate RPA2's contribution to genome stability:

• Experimental Design Strategy:

  • Compare normal cells with RPA2-depleted or mutated cells

  • Challenge cells with different genotoxic agents

  • Analyze both short-term responses and long-term consequences

• Acute Response Assessment:

  • Measure checkpoint activation (Chk1/Chk2 phosphorylation)

  • Analyze RPA2 phosphorylation by Western blot

  • Visualize damage foci formation by immunofluorescence

• Replication Analysis:

  • Monitor fork progression using DNA fiber analysis

  • Assess origin firing patterns

  • Measure ssDNA accumulation at stalled forks

• DNA Damage Quantification:

  • Measure γH2AX as a marker of DNA damage

  • Perform comet assays to quantify strand breaks

  • Analyze chromosomal aberrations by metaphase spreading

• Long-term Stability Assessment:

  • Track mutation rates using reporter systems

  • Measure micronuclei formation

  • Analyze copy number variations and structural rearrangements

• Cell Survival and Proliferation:

  • Colony formation assays

  • Growth curve analysis

  • Cell cycle distribution by flow cytometry

Recent advancements in antibody-cell conjugation technologies may offer novel approaches for studying RPA2 functions through the targeted delivery of specific inhibitors or modifiers to particular cell populations .